HiFiBiO Therapeutics Announces Oral Presentation at 2023 American Association for Cancer Research (AACR) Annual Meeting Apr 7, 2023 By Ivy Chen
Jan 6, 2023 By Vincent Tse HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603
Nov 18, 2022 By sarahjibrin HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors
Nov 18, 2022 By sarahjibrin HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors
Aug 15, 2022 By Rick Bowen HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors
Jan 10, 2022 By sarahjibrin HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB301001
Nov 1, 2021 By sarahjibrin HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301
Jun 17, 2021 By sarahjibrin FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
Jun 14, 2021 By sarahjibrin HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline with Two Lead Immuno-Oncology Programs and Validate its DIS® Approach in the Clinic
Oct 26, 2020 By sarahjibrin HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2 Neutralizing Antibody for the Treatment and Prevention of COVID-19
